Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 6Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Mesothelioma, Malignant 3Anus Neoplasms 3Rectal Neoplasms 2Colorectal Neoplasms 2Appendiceal Neoplasms 2Stomach Neoplasms 1Solid Neoplasm 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Necrosis 1HIV Infections 1Gastrointestinal Neoplasms 1Dermatitis 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anal Canal Carcinoma 1Adenocarcinoma 1

Interventions

Doxorubicin 13Zidovudine 12Vincristine 11Bleomycin 8Cyclophosphamide 7Interferon alpha-2 6Etoposide 5Dexamethasone 5sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Filgrastim 4Cytarabine 4Rituximab 3Prednisone 3Nivolumab 3interferon alfa-n1 2cabozantinib 2Thalidomide 2Isotretinoin 2Interleukin-2 2Fluorouracil 2Didanosine 2Bortezomib 2Biopsy 2Allopurinol 2prednylidene 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HIV Infections × Mitomycin × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡